Article
Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial.
Stroke - 1 Jul 2020
Meschia James F, Walton Ronald L, Farrugia Luca P, Ross Owen A, Elm Jordan J, Farrant Mary, Meurer William J, Lindblad Anne S, Barsan William, Ching Marilou, Gentile Nina, Ross Michael, Nahab Fadi, Easton J Donald, Kim Anthony S, Zurita Karla G, Cucchiara Brett, Johnston S Claiborne
Abstract excerpt
BACKGROUND AND PURPOSE: Clopidogrel is an antiplatelet drug that is metabolized to its active form by the CYP2C19 enzyme. The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) found a significant interaction between loss-of-function allele status for the CYP2C19 gene and the effect of dual antiplatelet therapy with aspirin and clopidogrel on the rate of early...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.